Search

e13629 Background: Cancer in adolescents and young adults (AYAOs) refers to patients diagnosed with a malignancy between 16 and 39 years old. This is thought to be 5% in the Western population. The exact incidence and distribution in Asia is uncertain although the WHO estimated 650 000 AYAs to be newly diagnosed in this part of the world in 2018. There is limited data on the incidence and epidemiology on AYAs in Asia, but it is known from the western literature that the distribution of cancer types, clinico-pathological features and outcomes in this population is very different. We therefore, sought to evaluate the pattern of cancer types among the different age groups of the AYA population seen in a high-volume single Asian tertiary cancer centre. Methods: We undertook a retrospective observational study of all patients diagnosed with cancer between 16 and 39 years old who presented to the National Cancer Centre Singapore (NCCS) from 1 January 2015 to 31 December 2019. Results: A total of 2583 cases was observed during the 5-year period. The male: female ratio was 1:1.75. The majority of the patients were between of 35-39 years (y) ( n= 1128, 44.0%). The most common cancer across the different age groups in females were sarcoma (16-19 y), hematologic malignancies (20-24 y) and breast cancer (25-29 y, 30-34 y and 35-39 y). The most common cancer across the different age groups in males were hematologic malignancies (16-19 y), germ cell tumours (20-24 y), germ cell tumours, hematologic malignancies and sarcoma (25-29 y), hematologic malignancies (30-34 y) and colorectal cancers (35-39 y). The majority of the patients presented were localized disease (38.3%), while 19.4% presented with lymphatic involvement. Amongst 507 (19.6%) patients presenting with metastatic disease, 126 patients have deceased. Conclusions: This population has unique characteristics compared to their geriatric and pediatric counterparts. With an increased incidence and expected longer survivals, more efforts are needed to better understand the clinicopathological features of the AYA population. This will enable us to better survival rates and long-term treatment outcomes.

e16651 Background: Hepatobiliary cancer is one of the common cancers within Asia with 80% of global cases occurring in the continent alone. Currently little is known about the incidence of hepatobiliary cancer in the Adolescent and Young Adults (AYA). In this population, hepatobiliary cancer may present in an insidious manner due to low suspicion and management may result in a higher likelihood of survivors with long-term treatment-related toxicities. We aim to highlight the clinicopathological features and treatment outcomes in this age-group in an Asian high-volume tertiary cancer institution. Methods: Patients diagnosed between the age of 16-39 with hepatobiliary cancers between 1st January 2015 to 31st December 2019 in a single-centre institution in Singapore were included in this study. Results: There was a total of 84 AYA patients with hepatobiliary tumours who were referred to our institution. Median age of diagnosis was 35 years old (n = 84). 32 patients (38.1%) had hepatocellular carcinoma, 22 patients (26.2%) had biliary tract tumours, 11 patients (13.1%) had neuroendocrine cancers while 19 patients (22.6%) had other tumour types (Figure 1). Male incidence was highest in all hepatobiliary AYAs (n = 56, 66.7%, p = 0.002) and hepatocellular carcinomas (n = 25, 78.1%, p = 0.001) (Table). 65 patients (77.4%) remain alive as of 31st December 2019. Conclusions: Patterns of hepatobiliary incidence differ between sexes. In the young AYA population, hepatocellular precursor cells may have sex-specific features affecting malignant potentials. More studies should be done to further elucidate the genomic and epidemiology of hepatobiliary tumours in the younger population of patients to better outcomes in this population. [Table: see text]

e13630 Background: Hematological malignancies is thought to be one of the more common Adolescent and Young Adult (AYA) cancers and constitute leukemias and lymphomas. However, little is known about its incidence and prevalence in Asia. We also do not have any data on its behavior or its prognosticators. The outcomes of this group of patients is also unknown when compared to the pediatrics or geriatrics, but is expected to be not as ideal. There is no consensus on whether this group of patients should be treated as pediatrics or as the older adults. We have sought to evaluate the prevalence and trends in a single large-volume tertiary cancer centre in Asia. Methods: We extracted data on all patients with cancer between 16-39 years old who were seen at our centre (National Cancer Centre Singapore) during the period of 1st January 2015 and 31st December 2019. In total, we had 2583 patients. We then excluded all other cancer types except those with a hematological malignancy and 5 other patients due to incomplete data. Results: There were 319 patients with a hematological malignancy. 153 (48%) were female and 166 were male(52%). Most of the patients presented between 30-39 years old (171, 53.6%). There were 54 (2.1%) leukemias and 265 (83.1%) lymphomas. Of those with leukemias, 46 (85.2%) had acute leukemia and 9 (14.8%) had chronic leukemias. Among the lymphoma patients, there were 194 (73.2%) Non Hodgkin Lymphoma (NHL) patients and 69 (26.0%) Hodgkin Lymphoma (HL) patients. There were 149 (46.7%) B Cell lymphomas and 38 (11.9%) T Cell lymphoma patients. The most common B cell Lymphomas is Diffuse Large B Cell Lymphoma (128, 85.9%) and the most common T Cell Lymphomas is Peripheral T-cell Lymphoma (28, 73.7% patients). Conclusions: AYAs with a hematological malignancy form a significant portion of the cancers we see in this age group. Yet, little information is available with regards to their clinico-pathological characteristics, especially in Asia. Work is underway to further elucidate these differences so that we can better their outcomes.